Liraglutide: clinical pharmacology and considerations for therapy (Q37933408)

25 August 2017

1 reference

title

Liraglutide: clinical pharmacology and considerations for therapy (English)

1 reference

25 August 2017

1 reference

1 reference

Evan M Sisson

1

1 reference

PubMed ID

21923591

25 August 2017

language of work or name

English

0 references

publication date

1 September 2011

1 reference

25 August 2017

1 reference

25 August 2017

31

1 reference

25 August 2017

9

1 reference

25 August 2017

896-911

1 reference

Incretins and their role in the management of diabetes

25 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Unraveling the science of incretin biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

The incretin system and its role in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Therapeutic strategies based on glucagon-like peptide 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in Type 2 diabetes management

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Addition of incretin therapy to metformin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Correct homeostasis model assessment (HOMA) evaluation uses the computer program

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Incretin hormone mimetics and analogues in diabetes therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Impact of therapeutic advances on hypoglycaemia in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Beta-cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes: comparison of surrogate markers with first-phase insulin secretion from an intravenous glucose tolerance test

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.9.896

21 January 2018

Identifiers

DOI

10.1592/PHCO.31.9.896

1 reference

25 August 2017

1 reference

PubMed ID

21923591